Consolidated results for the first quarter of the fiscal year ending June 2027. Revenue was 1,488 million yen, up 13.0% year-over-year. Operating income was 160 million yen, ordinary income was 133 million yen, and net income attributable to owners of parent was 126 million yen. Full-year forecasts remain unchanged from previously announced figures. Changes in the sales mix were driven by steady sales of equipment, reagents, and services in the life sciences and healthcare areas. Dividend forecast is 0 yen \/ 0 yen (year-end). Full-year forecasts for FY ending June 2027: revenue 5,650 million yen, operating income 350 million yen, net income 292 million yen, and EPS 10.67 yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7707","jir_company_name":"Precision System Science Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/7707-20261113-01.pdf","jir_short_summary":"Consolidated results for the first quarter of the fiscal year ending June 2027. Revenue was 1,488 million yen, up 13.0% year-over-year. Operating income was 160 million yen, ordinary income was 133 million yen, and net income attributable to owners of parent was 126 million yen. Full-year forecasts remain unchanged from previously announced figures. Changes in the sales mix were driven by steady sales of equipment, reagents, and services in the life sciences and healthcare areas. Dividend forecast is 0 yen \/ 0 yen (year-end). Full-year forecasts for FY ending June 2027: revenue 5,650 million yen, operating income 350 million yen, net income 292 million yen, and EPS 10.67 yen.","jir_summary":"### Overview of Results\nFor the cumulative consolidated first quarter, revenue was 1,488 million yen (Year-over-Year +13.0%), and gross profit was 532 million yen (Year-over-Year +29.6%), supported by steady sales related to the PSS platform for equipment, reagents, and services. Selling, general and administrative expenses rose to 371 million yen (Year-over-Year +4.8%) due to increases in personnel and logistics expenses; nevertheless, operating income expanded to 160 million yen (Year-over-Year +187.2%). Ordinary income was 133 million yen, and net income attributable to owners of parent for the quarter was 126 million yen, both showing significant increases. The full-year outlook remains unchanged from prior forecasts.\n\n### Segment Information and Financial Position\nDuring the period, revenue by segment was: Equipment 719 million yen (Year-over-Year: +21.0%), Reagents & Consumables 610 million yen (Year-over-Year: +22.6%), and Services & Others 157 million yen (Year-over-Year: -29.7%). Total assets were 5,874 million yen, net assets were 4,157 million yen, and the equity ratio was a healthy 70.8%. Repayment of short- and long-term borrowings progressed, resulting in total liabilities of 1,716 million yen.","jir_financial_highlights":"Revenue: 1,488 million yen (Year-over-Year +13.0%)\nOperating Income: 160 million yen (Year-over-Year +187.2%)\nOrdinary Income: 133 million yen (Year-over-Year +128.4%)\nNet Income Attributable to Owners of Parent (quarter): 126 million yen (Year-over-Year +132.8%)\nEquity Ratio: 70.8% (Approx. +1.0pt Year-over-Year)","jir_category":"","jir_hashtags":"#PrecisionSystemScience, #LifeSciences, #Earnings, #QuarterlyResults","jir_key_figures":"Revenue: 1,488 million yen\nOperating Income: 160 million yen\nOrdinary Income: 133 million yen\nNet Income Attributable to Owners of Parent (quarter): 126 million yen\nEquity Ratio: 70.8%\nFull-year Revenue Forecast: 5,650 million yen\nFull-year Operating Income Forecast: 350 million yen\nFull-year Net Income Forecast: 292 million yen\nEarnings per Share: 10.67 yen","jir_meta_title":"Precision System Science Co., Ltd. Q1 FY2027 Financial Summary | Revenue 1,488 million yen, Operating Income 160 million yen","jir_meta_description":"Revenue from PSS platform-related equipment, reagents, and services increased, supported by steady demand in the life sciences and healthcare sectors. Summary of Q1 key metrics and full-year outlook.","jir_og_title":"Precision System Science Co., Ltd. | Q1 Financial Results","jir_og_description":"In Q1, revenue reached 1,488 million yen and operating income was 160 million yen. Full-year forecasts remain unchanged. Business mix improvements continued across equipment, reagents, and services.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026\/7\\\",\\\"2026\/8\\\",\\\"2026\/9\\\",\\\"2026\/10\\\",\\\"2026\/11\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[1488,1400,1500,1520,1490]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026\/7\\\",\\\"2026\/8\\\",\\\"2026\/9\\\",\\\"2026\/10\\\",\\\"2026\/11\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[160,100,120,130,160]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Revenue by Segment\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Equipment\\\",\\\"Reagents & Consumables\\\",\\\"Services & Others\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[719,610,157]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Gross Profit Margin\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026\/7\\\",\\\"2026\/9\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Gross Profit Margin\\\",\\\"data\\\":[31.15,35.78]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"table\", \"jir_chart_title\": \"Comparison of Full-year Forecast and Results\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"table\\\",\\\"data\\\":{\\\"columns\\\":[\\\"Metric\\\",\\\"Full-year Forecast\\\",\\\"Results\\\"],\\\"rows\\\":[[\\\"Revenue\\\",\\\"5,650 million yen\\\",\\\"1,488 million yen\\\"]]},\\\"options\\\":{}}\"}]","ir_related_company":59741,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-153292","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n